Chamath Palihapitiya
· Chamath Palihapitiya
· June 05, 2026 at 15:11
· ⏱ 3 min read
| Read on Substack ↗
Summary
Aging is the single largest shared risk factor for cancer, heart disease, dementia, and type 2 diabetes, yet longevity biotech receives only ~0.25% of global biomedical R&D. The article argues that slowing aging could delay multiple diseases simultaneously and add $400B/year to U.S. GDP, but proving it in humans faces regulatory and patent hurdles that make it the hardest therapy to ever validate. For markets, this means the sector remains a high-risk, long-duration thesis with no near-term catalysts, and investors should not expect actionable trade ideas from the current state of research.
•Aging is the largest risk factor for major diseases, ahead of smoking, blood pressure, or cholesterol; curing cancer outright would only extend average life expectancy by ~3 years because aging continues to compound risk.
•Slowing human aging by one year is estimated to add about $400B annually to U.S. GDP.
•Calorie restriction in mice extends lifespan by 50–65%, and single gene changes or late-life rapamycin can produce similar effects.
•Some species (naked mole rat, certain turtles) show negligible senescence, with flat mortality risk over time.
•Global research on the biology of aging receives only $1–2B per year, roughly 0.25% of the $350–400B in total biomedical R&D, despite aging being upstream of most developed-world health spending.
•Proving a drug slows human aging would require a decades-long trial that outlasts its patent, and no regulator currently recognizes aging as a treatable condition.